FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288388857> ?p ?o ?g. }

• W4288388857 endingPage "2241" @default.
• W4288388857 startingPage "2233" @default.
• W4288388857 abstract "Introduction: Cholangiocarcinoma (CCA) is the second most common type of primary liver cancer. Several factors, such as epigenetic changes in promoter genes, gene expression, and microRNAs (miR), can contribute to genomic instability in cancer. This study aimed at evaluating the expression of VEGF, miRs 145-3p, and 101-3p in patients with CCA and their potential as biomarkers for diagnosis and prognosis of CCA. Material and methods : Sixty two patients were studied. Out of these 62 patients, 41 cases had confirm CCA and 21 cases had hepatopathies complications. The RNA was extracted from a paraffined tissue block, and then the synthesis of cDNA was performed. The analysis of the expression of VEGF, miR-145-3p, and miR-101-3p was carried out by polymerase chain reaction in real time. Results: The findings revealed that miRs 145-3p and 101-3p were under expressed in the case group compared to the control group (0.46; 0.17; P = 0.0001, respectively). VEGF was overexpressed in the case group compared to the control group (11.8; P = 0.0001). An increase in miR-145-3p expression level was observed in patients with perihilar CCA compared to those with distal CCA (0.51 ± 0.41; 0.17 ± 0.13; P = 0.0698). Survival rate analysis showed that 41.9% of patients with intrahepatic CCA and 31.5% of patients with extrahepatic CCA were free from death within 11 months, leading to a significant difference (P> 0.05). Conclusion: The underexpression of miRNAs, tumor suppressors, the overexpression of VEGF, smoking, and aging were associated with CCA based on our findings. It seems that the reduced expression of the studies miRNAs and increased expression of VEGF can contribute to a decrease in survival rate of patients with tumor in their intrahepatic bile ducts." @default.
• W4288388857 created "2022-07-29" @default.
• W4288388857 creator A5001098008 @default.
• W4288388857 creator A5001805736 @default.
• W4288388857 creator A5003835798 @default.
• W4288388857 creator A5004936677 @default.
• W4288388857 creator A5010251488 @default.
• W4288388857 creator A5034611851 @default.
• W4288388857 creator A5042166089 @default.
• W4288388857 creator A5046477501 @default.
• W4288388857 creator A5057597260 @default.
• W4288388857 creator A5059058400 @default.
• W4288388857 creator A5067063728 @default.
• W4288388857 creator A5071565947 @default.
• W4288388857 creator A5080350801 @default.
• W4288388857 creator A5086451946 @default.
• W4288388857 creator A5089003351 @default.
• W4288388857 creator A5089219942 @default.
• W4288388857 creator A5089963479 @default.
• W4288388857 date "2022-07-01" @default.
• W4288388857 modified "2023-10-15" @default.
• W4288388857 title "Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma" @default.
• W4288388857 cites W1968252084 @default.
• W4288388857 cites W2037570081 @default.
• W4288388857 cites W2041795060 @default.
• W4288388857 cites W2052158431 @default.
• W4288388857 cites W2162451445 @default.
• W4288388857 cites W2216120881 @default.
• W4288388857 cites W2298991506 @default.
• W4288388857 cites W2337387091 @default.
• W4288388857 cites W2417316388 @default.
• W4288388857 cites W2581503912 @default.
• W4288388857 cites W2588040452 @default.
• W4288388857 cites W2590486844 @default.
• W4288388857 cites W2627977620 @default.
• W4288388857 cites W271304362 @default.
• W4288388857 cites W2743874890 @default.
• W4288388857 cites W2766085363 @default.
• W4288388857 cites W2789475596 @default.
• W4288388857 cites W2885058918 @default.
• W4288388857 cites W2889296926 @default.
• W4288388857 cites W2906940004 @default.
• W4288388857 cites W2921534199 @default.
• W4288388857 cites W2945635332 @default.
• W4288388857 cites W2956169327 @default.
• W4288388857 cites W2973485115 @default.
• W4288388857 cites W2982348459 @default.
• W4288388857 cites W2982481372 @default.
• W4288388857 cites W3005292978 @default.
• W4288388857 cites W3010342924 @default.
• W4288388857 cites W3011801946 @default.
• W4288388857 cites W3012695620 @default.
• W4288388857 cites W3015521901 @default.
• W4288388857 cites W3023456580 @default.
• W4288388857 cites W3024003116 @default.
• W4288388857 cites W3039360174 @default.
• W4288388857 cites W3040375254 @default.
• W4288388857 cites W3116321956 @default.
• W4288388857 cites W3006170433 @default.
• W4288388857 doi "https://doi.org/10.31557/apjcp.2022.23.7.2233" @default.
• W4288388857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35901327" @default.
• W4288388857 hasPublicationYear "2022" @default.
• W4288388857 type Work @default.
• W4288388857 citedByCount "3" @default.
• W4288388857 countsByYear W42883888572022 @default.
• W4288388857 countsByYear W42883888572023 @default.
• W4288388857 crossrefType "journal-article" @default.
• W4288388857 hasAuthorship W4288388857A5001098008 @default.
• W4288388857 hasAuthorship W4288388857A5001805736 @default.
• W4288388857 hasAuthorship W4288388857A5003835798 @default.
• W4288388857 hasAuthorship W4288388857A5004936677 @default.
• W4288388857 hasAuthorship W4288388857A5010251488 @default.
• W4288388857 hasAuthorship W4288388857A5034611851 @default.
• W4288388857 hasAuthorship W4288388857A5042166089 @default.
• W4288388857 hasAuthorship W4288388857A5046477501 @default.
• W4288388857 hasAuthorship W4288388857A5057597260 @default.
• W4288388857 hasAuthorship W4288388857A5059058400 @default.
• W4288388857 hasAuthorship W4288388857A5067063728 @default.
• W4288388857 hasAuthorship W4288388857A5071565947 @default.
• W4288388857 hasAuthorship W4288388857A5080350801 @default.
• W4288388857 hasAuthorship W4288388857A5086451946 @default.
• W4288388857 hasAuthorship W4288388857A5089003351 @default.
• W4288388857 hasAuthorship W4288388857A5089219942 @default.
• W4288388857 hasAuthorship W4288388857A5089963479 @default.
• W4288388857 hasBestOaLocation W42883888571 @default.
• W4288388857 hasConcept C104317684 @default.
• W4288388857 hasConcept C121608353 @default.
• W4288388857 hasConcept C126322002 @default.
• W4288388857 hasConcept C143998085 @default.
• W4288388857 hasConcept C145059251 @default.
• W4288388857 hasConcept C146304588 @default.
• W4288388857 hasConcept C150194340 @default.
• W4288388857 hasConcept C167734588 @default.
• W4288388857 hasConcept C41091548 @default.
• W4288388857 hasConcept C48023723 @default.
• W4288388857 hasConcept C49105822 @default.
• W4288388857 hasConcept C54355233 @default.
• W4288388857 hasConcept C71924100 @default.

• next